Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
15 June 2021 – Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity.
Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer
/in Press releases /by resilienceIndustry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly Established U.S. Office Cambridge, UK and Boston, Massachusetts, June 22, 2021 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of […]
Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study
/in Press releases /by resilienceCambridge, UK, 5 May 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.